Aligos Therapeutics, Inc. APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition
Aligos Therapeutics, Inc. (ALGS) reported APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition of $1.23 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition · last filed 2026-08-06
- Aligos Therapeutics, Inc. apic, share-based payment arrangement, other, increase for cost recognition for the quarter ending 2026-06-30 was $1.23M, a 17.05% increase year-over-year.
- Aligos Therapeutics, Inc. apic, share-based payment arrangement, other, increase for cost recognition for the quarter ending 2026-03-31 was $1.23M, a 34.76% increase year-over-year.
- Aligos Therapeutics, Inc. apic, share-based payment arrangement, other, increase for cost recognition for the quarter ending 2025-09-30 was $1.27M, a 33.40% decline year-over-year.
- Aligos Therapeutics, Inc. apic, share-based payment arrangement, other, increase for cost recognition for the quarter ending 2025-06-30 was $1.05M, a 45.26% decline year-over-year.
- Aligos Therapeutics, Inc. apic, share-based payment arrangement, other, increase for cost recognition for fiscal 2025 was $4.54M, a 42.87% decline from fiscal 2024.
- Aligos Therapeutics, Inc. apic, share-based payment arrangement, other, increase for cost recognition for fiscal 2024 was $7.95M, a 32.64% decline from fiscal 2023.
- Aligos Therapeutics, Inc. apic, share-based payment arrangement, other, increase for cost recognition for fiscal 2023 was $11.80M, a 12.86% decline from fiscal 2022.
- Aligos Therapeutics, Inc. apic, share-based payment arrangement, other, increase for cost recognition for fiscal 2022 was $13.54M, a 7.97% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.23M 10-Q · filed 2026-08-06 | $2.45M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $1.23M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $4.54M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $1.27M 10-Q · filed 2025-11-06 | $2.32M derived: sum of 2 quarters · filed 2026-08-06 | $3.23M derived: sum of 3 quarters · filed 2026-08-06 | $4.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.05M 10-Q · filed 2026-08-06 | $1.96M derived: sum of 2 quarters · filed 2026-08-06 | $3.59M derived: sum of 3 quarters · filed 2026-08-06 | $5.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $909.00K 10-Q · filed 2026-08-06 | $2.54M derived: sum of 2 quarters · filed 2026-08-06 | $4.44M derived: sum of 3 quarters · filed 2026-08-06 | $6.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-12-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.53M derived: sum of 2 quarters · filed 2026-03-05 | $5.45M derived: sum of 3 quarters · filed 2026-03-05 | $7.95M 10-K · filed 2026-03-05 |
| 2024-09-30 | $1.90M 10-Q · filed 2025-11-06 | $3.82M derived: sum of 2 quarters · filed 2025-11-06 | $6.32M 10-Q · filed 2024-11-06 | $8.76M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.92M 10-Q · filed 2025-11-06 | $4.42M 10-Q · filed 2024-08-06 | $6.86M derived: sum of 3 quarters · filed 2025-11-06 | $9.74M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-03-31 | $2.50M 10-Q · filed 2025-11-06 | $4.94M derived: sum of 2 quarters · filed 2025-11-06 | $7.82M derived: sum of 3 quarters · filed 2025-11-06 | $10.80M derived: sum of 4 quarters · filed 2025-11-06 |
| 2023-12-31 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $5.32M derived: sum of 2 quarters · filed 2025-03-10 | $8.30M derived: sum of 3 quarters · filed 2025-03-10 | $11.80M 10-K · filed 2025-03-10 |
| 2023-09-30 | $2.88M 10-Q · filed 2024-11-06 | $5.86M derived: sum of 2 quarters · filed 2024-11-06 | $9.36M 10-Q · filed 2024-11-06 | $12.60M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $2.98M 10-Q · filed 2024-08-06 | $6.48M 10-Q · filed 2024-08-06 | $9.71M derived: sum of 3 quarters · filed 2024-08-06 | $12.98M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $3.50M 10-Q · filed 2024-05-07 | $6.74M derived: sum of 2 quarters · filed 2024-05-07 | $10.01M derived: sum of 3 quarters · filed 2024-05-07 | $13.56M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $3.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $6.51M derived: sum of 2 quarters · filed 2024-03-12 | $10.06M derived: sum of 3 quarters · filed 2024-03-12 | $13.54M 10-K · filed 2024-03-12 |
| 2022-09-30 | $3.27M 10-Q · filed 2023-11-02 | $6.83M derived: sum of 2 quarters · filed 2023-11-02 | $10.31M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $3.55M 10-Q · filed 2023-08-03 | $7.03M 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $3.48M 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $12.54M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |